All In Biotech

NDA 021187 · Organon USA Organon

Nuvaring

Ethinyl Estradiol, Etonogestrel · Vaginal · Progestin; Estrogen

Novel

Last checked: Nov 20, 2026Latest source record: May 31, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Oct 3, 2001

Approved uses

4

Original approval plus efficacy supplements

Registered trials

501

113 Phase 3, 20 recruiting

FAERS reports

21,475

10,461 serious, 280 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including NuvaRing, should not be used by women who are over 35 years of age and smoke. [See Contraindications (4) .] WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. Women over 35 years old who smoke should not use NuvaRing. ( 4 ) Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. ( 4 )

What it is approved for

From the label in effect Nov 14, 2025.

FOR VAGINAL USE ONLY NuvaRing ® is indicated for use by females of reproductive age to prevent pregnancy. NuvaRing is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women to prevent pregnancy. ( 1 )

Mechanism: Combination hormonal contraceptives act by suppression of gonadotropins. Although the primary effect of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NUVARING · ETHINYL ESTRADIOL 0.015MG/24HR; ETONOGESTREL 0.12MG/24HR · RING, VAGINAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ethinyl Estradiol" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pulmonary embolism3,951
  • deep vein thrombosis2,659
  • inappropriate schedule of drug administration2,229
  • device expulsion1,366
  • no adverse event1,204
  • headache1,151
  • metrorrhagia1,132
  • incorrect drug administration duration1,017
  • nausea1,012
  • unintended pregnancy956
  • depression910
  • anxiety862

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,304
2005130
2006255
2007173
2008190
2009483
2010678
20111,020
20121,697
20132,982
20143,782
20151,561
20161,659
20171,512
20181,184
2019747
2020690
2021347
2022315
2023186
2024184
2025164
2026232

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nuvaring (Etonogestrel/Ethinyl Estradiol)

2024 spending

$168K

Beneficiaries

148

520 claims

Per beneficiary

$1,135

$152.65 per unit

View as table
YearSpending
2020$0
2021$58,779
2022$233,115
2023$196,550
2024$167,917

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,104 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.